Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection
Immunomedics, Inc. (Nasdaq: IMMU), today announced that a blood test based on the Company's humanized antibody, clivatuzumab, correctly identified nearly two thirds of patients with early stage pancreatic cancer. Dr. David V. Gold, Director of Laboratory Administration and Senior Member of the Garden State Cancer Center in Morris Plains, NJ, presented the study at the 2012 Gastrointestinal Cancers Symposium media presscast. The scientific presentation will be given on January 20, 2012.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.